For the nasal sprayform of the vaccine, there is evidence of high protection for children aged 6 months to 7 years, inconsistent evidence of protection in adults 60 years of age and older, and a lack of evidence of protection in individuals between 8 and 59 years of age, the study says.
In the minutes of its latest meeting the JCVI says the vaccine has "a good safety profile" and may be more widely accepted by parents and children because it is given in the form of a nasal spray.